3,706 reports of this reaction
13.3% of all LEDIPASVIR AND SOFOSBUVIR reports
#2 most reported adverse reaction
HEADACHE is the #2 most commonly reported adverse reaction for LEDIPASVIR AND SOFOSBUVIR, manufactured by Gilead Sciences, Inc. There are 3,706 FDA adverse event reports linking LEDIPASVIR AND SOFOSBUVIR to HEADACHE. This represents approximately 13.3% of all 27,933 adverse event reports for this drug.
Patients taking LEDIPASVIR AND SOFOSBUVIR who experience headache should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HEADACHE is a frequently reported adverse event for LEDIPASVIR AND SOFOSBUVIR, accounting for a significant proportion of all reports.
In addition to headache, the following adverse reactions have been reported for LEDIPASVIR AND SOFOSBUVIR:
The following drugs have also been linked to headache in FDA adverse event reports:
HEADACHE has been reported as an adverse event in 3,706 FDA reports for LEDIPASVIR AND SOFOSBUVIR. This does not prove causation, but indicates an association observed in post-market surveillance data.
HEADACHE accounts for approximately 13.3% of all adverse event reports for LEDIPASVIR AND SOFOSBUVIR, making it one of the most commonly reported side effect.
If you experience headache while taking LEDIPASVIR AND SOFOSBUVIR, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.